It is undoubtedly helpful to have people on your board who understand the regulatory mechanisms and industry (leaving aside how well the Theranos board actually does this)

Composition of a board is tricky though. In a case like this you would hope to have equal, if not dominant, representation of people who are strong on the science. Anything else is a bit of a red flag.